Benzinga | Jan 6, 2022 06:02AM EST

Morgan Stanley Downgrades Gilead Sciences to Equal-Weight, Lowers Price Target to $74

Morgan Stanley analyst Matthew Harrison downgrades Gilead Sciences (NASDAQ:GILD) from Overweight to Equal-Weight and lowers the price target from $84 to $74.